Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock
Sacubitril/valsartan is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for heart failure. We present a case of a patient with NYHA class IV systolic heart failure who was refractory to all other classes of heart failure medications and was...
Main Authors: | H. A. Rawal, A. G. Kocheril |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | Case Reports in Cardiology |
Online Access: | http://dx.doi.org/10.1155/2018/8231576 |
Similar Items
-
Pheochromocytoma Presenting as Acute Heart Failure Leading to Cardiogenic Shock and Multiorgan Failure
by: Jochen Steppan, et al.
Published: (2011-01-01) -
Extracorporeal Membrane Oxygenation as a Bridge for Heart Failure and Cardiogenic Shock
by: Zhao-peng Zhong, et al.
Published: (2016-01-01) -
Effectiveness of sacubitril–valsartan in cancer patients with heart failure
by: Ana Martín‐Garcia, et al.
Published: (2020-04-01) -
Outcome differences in acute vs. acute on chronic heart failure and cardiogenic shock
by: Tara L. Jones, et al.
Published: (2020-06-01) -
Predicting survival in patients with acute decompensated heart failure complicated by cardiogenic shock
by: Nuccia Morici, et al.
Published: (2021-06-01)